Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Chia Siang Kow; Dinesh Sangarran Ramachandram; Syed Shahzad Hasan; Kaeshaelya Thiruchelvam

doi:10.1093/ijpp/riae003

Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam

Research output: Contribution to journal › Review article › peer-review

Abstract

Objectives: To determine risks associated with uricosurics in COVID-19 patients. Methods: A systematic review and meta-analysis was conducted by systematically searching electronic databases. Key findings: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94). Conclusions: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.

Original language	English
Pages (from-to)	259-264
Number of pages	6
Journal	International Journal of Pharmacy Practice
Volume	32
Issue number	3
Early online date	4 Mar 2024
DOIs	https://doi.org/10.1093/ijpp/riae003
Publication status	Published - 1 Jun 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/ijpp/riae003Licence: CC BY

Cite this

@article{94e58fda6f50449c87c7bdaeaec2d455,

title = "Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials",

abstract = "Objectives: To determine risks associated with uricosurics in COVID-19 patients. Methods: A systematic review and meta-analysis was conducted by systematically searching electronic databases. Key findings: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95\% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95\% CI: 0.65-0.94). Conclusions: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.",

keywords = "COVID-19, mortality, uricosuric",

author = "Kow, \{Chia Siang\} and Ramachandram, \{Dinesh Sangarran\} and Hasan, \{Syed Shahzad\} and Kaeshaelya Thiruchelvam",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Oxford University Press on behalf of the Royal Pharmaceutical Society.",

year = "2024",

month = jun,

day = "1",

doi = "10.1093/ijpp/riae003",

language = "English",

volume = "32",

pages = "259--264",

journal = "International Journal of Pharmacy Practice",

issn = "0961-7671",

publisher = "Oxford University Press",

number = "3",

}

Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. / Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad et al.
In: International Journal of Pharmacy Practice, Vol. 32, No. 3, 01.06.2024, p. 259-264.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Impact of uricosurics on mortality outcomes in patients with COVID-19

T2 - a systematic review and meta-analysis of randomized controlled trials

AU - Kow, Chia Siang

AU - Ramachandram, Dinesh Sangarran

AU - Hasan, Syed Shahzad

AU - Thiruchelvam, Kaeshaelya

PY - 2024/6/1

Y1 - 2024/6/1

N2 - Objectives: To determine risks associated with uricosurics in COVID-19 patients. Methods: A systematic review and meta-analysis was conducted by systematically searching electronic databases. Key findings: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94). Conclusions: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.

AB - Objectives: To determine risks associated with uricosurics in COVID-19 patients. Methods: A systematic review and meta-analysis was conducted by systematically searching electronic databases. Key findings: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94). Conclusions: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.

KW - COVID-19

KW - mortality

KW - uricosuric

UR - https://www.scopus.com/pages/publications/85192420347

U2 - 10.1093/ijpp/riae003

DO - 10.1093/ijpp/riae003

M3 - Review article

C2 - 38438314

AN - SCOPUS:85192420347

SN - 0961-7671

VL - 32

SP - 259

EP - 264

JO - International Journal of Pharmacy Practice

JF - International Journal of Pharmacy Practice

IS - 3

ER -

Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this